Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 85

1.

Trace amine metabolism in Parkinson's disease: low circulating levels of octopamine in early disease stages.

D'Andrea G, Nordera G, Pizzolato G, Bolner A, Colavito D, Flaibani R, Leon A.

Neurosci Lett. 2010 Jan 29;469(3):348-51. doi: 10.1016/j.neulet.2009.12.025. Epub 2009 Dec 21.

PMID:
20026245
2.

Elevated levels of circulating trace amines in primary headaches.

D'Andrea G, Terrazzino S, Leon A, Fortin D, Perini F, Granella F, Bussone G.

Neurology. 2004 May 25;62(10):1701-5.

PMID:
15159465
3.

Slowing of oscillatory brain activity is a stable characteristic of Parkinson's disease without dementia.

Stoffers D, Bosboom JL, Deijen JB, Wolters EC, Berendse HW, Stam CJ.

Brain. 2007 Jul;130(Pt 7):1847-60. Epub 2007 Apr 5.

PMID:
17412733
4.

Abnormal platelet trace amine profiles in migraine with and without aura.

D'Andrea G, Granella F, Leone M, Perini F, Farruggio A, Bussone G.

Cephalalgia. 2006 Aug;26(8):968-72.

PMID:
16886933
5.
6.

Serum trace element levels and the complexity of inter-element relations in patients with Parkinson's disease.

Hegde ML, Shanmugavelu P, Vengamma B, Rao TS, Menon RB, Rao RV, Rao KS.

J Trace Elem Med Biol. 2004;18(2):163-71.

PMID:
15646263
7.

A study of dopaminergic sensitivity in Parkinson's disease: comparison in "de novo" and levodopa-treated patients.

Llau ME, Durrieu G, Tran MA, Senard JM, Rascol O, Montastruc JL.

Clin Neuropharmacol. 1996 Oct;19(5):420-7.

PMID:
8889285
8.

The role of tyrosine metabolism in the pathogenesis of chronic migraine.

D'Andrea G, D'Amico D, Bussone G, Bolner A, Aguggia M, Saracco MG, Galloni E, De Riva V, Colavito D, Leon A, Rosteghin V, Perini F.

Cephalalgia. 2013 Aug;33(11):932-7. doi: 10.1177/0333102413480755. Epub 2013 Mar 14.

PMID:
23493762
9.

Plasma HVA levels following debrisoquine administration do not reflect cerebral dopamine loss in early Parkinson's disease.

Rose S, Hindmarsh JG, Steiger MJ, Bhatt M, Quinn NP, Jenner P, Marsden CD.

Clin Neuropharmacol. 1994 Jun;17(3):260-9.

PMID:
9316671
10.

Biochemistry of postmortem brains in Parkinson's disease: historical overview and future prospects.

Nagatsu T, Sawada M.

J Neural Transm Suppl. 2007;(72):113-20. Review.

PMID:
17982884
11.

Expression analysis of suppression of tumorigenicity 13 gene in patients with Parkinson's disease.

Shadrina MI, Filatova EV, Karabanov AV, Slominsky PA, Illarioshkin SN, Ivanova-Smolenskaya IA, Limborska SA.

Neurosci Lett. 2010 Apr 12;473(3):257-9. doi: 10.1016/j.neulet.2010.02.061. Epub 2010 Mar 1.

PMID:
20193743
12.

The fate of striatal dopaminergic neurons in Parkinson's disease and Huntington's chorea.

Huot P, Lévesque M, Parent A.

Brain. 2007 Jan;130(Pt 1):222-32. Epub 2006 Dec 2.

PMID:
17142832
13.

Plasma levels of inorganic sulfates in patients with Parkinson's disease.

Jiménez-Jiménez FJ, Molina JA, Aguilar MV, Jorge-Santamaría A, Mateos-Vega CJ, González-Muñoz MJ, Cabrera-Valdivia F, Ayuso-Peralta L, Benito J, Vázquez A, et al.

Acta Neurol Scand. 1995 Nov;92(5):369-71.

PMID:
8610488
14.

HPLC electrochemical detection of trace amines in human plasma and platelets and expression of mRNA transcripts of trace amine receptors in circulating leukocytes.

D'Andrea G, Terrazzino S, Fortin D, Farruggio A, Rinaldi L, Leon A.

Neurosci Lett. 2003 Jul 31;346(1-2):89-92.

PMID:
12850555
15.

The relation of testosterone levels with fatigue and apathy in Parkinson's disease.

Kenangil G, Orken DN, Ur E, Forta H, Celik M.

Clin Neurol Neurosurg. 2009 Jun;111(5):412-4. doi: 10.1016/j.clineuro.2008.11.019. Epub 2009 Jan 8.

PMID:
19131155
16.

Circulating interleukin-10 and interleukin-12 in Parkinson's disease.

Rentzos M, Nikolaou C, Andreadou E, Paraskevas GP, Rombos A, Zoga M, Tsoutsou A, Boufidou F, Kapaki E, Vassilopoulos D.

Acta Neurol Scand. 2009 May;119(5):332-7. doi: 10.1111/j.1600-0404.2008.01103.x. Epub 2008 Oct 23.

PMID:
18976327
17.
18.

[Case-control study of markers of oxidative stress and metabolism of blood iron in Parkinson's disease].

Larumbe Ilundáin R, Ferrer Valls JV, Viñes Rueda JJ, Guerrero D, Fraile P.

Rev Esp Salud Publica. 2001 Jan-Feb;75(1):43-53. Spanish.

19.

Plasma alpha-synuclein is decreased in subjects with Parkinson's disease.

Li QX, Mok SS, Laughton KM, McLean CA, Cappai R, Masters CL, Culvenor JG, Horne MK.

Exp Neurol. 2007 Apr;204(2):583-8. Epub 2006 Dec 19.

PMID:
17258710
20.

Circulating plasma factors in Parkinson's disease enhance nitric oxide release of normal human neutrophils.

Gatto EM, Riobó NA, Carreras MC, Schöpfer FJ, Pargament GA, Poderoso JJ.

J Neurol Sci. 1999 May 1;165(1):66-70.

PMID:
10426150

Supplemental Content

Support Center